EUVIMEDEUVIMED entdecken
Crossref

Two Cases of Bullous Pemphigoid Induced by Vildagliptin

Aslı ÜNAL DOĞRUK, Özlem TARÇIN, Gülşen TÜKENMEZ DEMİRCİ, Ebru DEMİRALAY, Ayşe Tülin MANSUR, Şemsi YILMAZ, Nilgün GÜVENER DEMİRAĞ

Endocrinology Research and Practice · 2018

DOI: 10.25179/tjem.2017-56526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology Research and Practice, 2018. Verfasst von Aslı ÜNAL DOĞRUK und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Bullous pemphigoid is an autoimmune blistering disorder that commonly develops in elderly subjects who are prone to an increased risk of mortality and morbidity. Although a few cases of dipeptidyl peptidase-4 inhibitors have been reported earlier, the etiology of bullous pemphigoid is not entirely clear. Case Report 1: An 81-years-old man presented with bullous pemphigoid after 28 months of treatment with repaglinide, vildagliptin, and metformin. Since his skin lesions were not improving with topical treatment of clobetasol propionate 0.05% ointment, so then he was started on methylprednisolone and azathioprine; however, the skin lesions sustained even then. Remission was achieved only after the withdrawal of vildagliptin. Case Report 2: A 64-years old man who was on insulin glargine, insulin aspart, and vildagliptin for 12 months, presented with BP of skin and laryngeal mucosa. The skin lesions were resolved after discontinuation of vildagliptin, but the laryngeal involvement continued to exist. Methylprednisolone and azathioprine treatment, for mucosal lesions, were started and continued for six months.

Conclusion

Only a few cases of gliptin induced bullous pemphigoid are present in the literature. One of our cases is the first to demonstrate the latest onset of vildagliptin associated skin reactions while the other case is the first to demonstrate vildagliptin associated mucosal involvement. The exact mechanism of these reactions is unknown, however, it is proposed that it could be caused by modified immune responses. Our cases support the finding that there is a risk of bullous pemphigoid development in patients exposed to vildagliptin. Therefore, it is important to be aware of this risk and stop the vildagliptin treatment in such patients.

Zitieren

APA

DOĞRUK, A. Ü., TARÇIN, Ö., DEMİRCİ, G. T., DEMİRALAY, E., MANSUR, A. T., YILMAZ, Ş., & DEMİRAĞ, N. G. (2018). Two Cases of Bullous Pemphigoid Induced by Vildagliptin. Endocrinology Research and Practice. https://doi.org/10.25179/tjem.2017-56526

Vancouver

DOĞRUK AÜ, TARÇIN Ö, DEMİRCİ GT, DEMİRALAY E, MANSUR AT, YILMAZ Ş, et al. Two Cases of Bullous Pemphigoid Induced by Vildagliptin. Endocrinology Research and Practice. 2018. doi:10.25179/tjem.2017-56526

BibTeX
@article{DORUK2018,
  author = {DOĞRUK, Aslı ÜNAL and TARÇIN, Özlem and DEMİRCİ, Gülşen TÜKENMEZ and DEMİRALAY, Ebru and MANSUR, Ayşe Tülin and YILMAZ, Şemsi and DEMİRAĞ, Nilgün GÜVENER},
  title = {Two Cases of Bullous Pemphigoid Induced by Vildagliptin},
  journal = {Endocrinology Research and Practice},
  year = {2018},
  doi = {10.25179/tjem.2017-56526}
}
Kostenlos starten →